132 related articles for article (PubMed ID: 36706266)
1. Severe Recurrent Nocturnal Hypoglycemia During Chemotherapy With 6-mercaptopurine in 2 Children With Acute Lymphoblastic Leukemia.
Albiroty K; Al Sabahi A
J Pediatr Hematol Oncol; 2023 Apr; 45(3):162-163. PubMed ID: 36706266
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia.
Zhang M; Bostrom B
F1000Res; 2019; 8():176. PubMed ID: 30828444
[TBL] [Abstract][Full Text] [Related]
3. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
4. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
5. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
7. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
8. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
Melachuri S; Gandrud L; Bostrom B
Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
10. Severe hypoglycemic seizures in a child receiving 6-mercaptopurine.
El-Bitar MK; Muwakkit SA; Dabbagh O
J Pediatr Hematol Oncol; 2011 Mar; 33(2):e75-6. PubMed ID: 21343747
[TBL] [Abstract][Full Text] [Related]
11. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.
Kamojjala R; Bostrom B
J Pediatr Hematol Oncol; 2021 Apr; 43(3):95-100. PubMed ID: 33750748
[TBL] [Abstract][Full Text] [Related]
13. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
15. Severe mercaptopurine-induced hypoglycemia in acute lymphoblastic leukemia.
Rebelo A; Oliveira J; Sousa C
Pediatr Hematol Oncol; 2020 Apr; 37(3):245-247. PubMed ID: 31984843
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
17. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
[TBL] [Abstract][Full Text] [Related]
18. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
Schmiegelow K; Bruunshuus I
Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
[TBL] [Abstract][Full Text] [Related]
19. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance.
Macdougall LG; McElligott SE; Ross E; Greeff MC; Poole JE
Ther Drug Monit; 1992 Oct; 14(5):371-5. PubMed ID: 1448843
[TBL] [Abstract][Full Text] [Related]
20. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
